Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acute Exacerbation of COPD Clear all
Completed Not applicable Interventional Results available

An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD

NCT03207776
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Usual Care, COPD Clinical Pathway
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
4,832 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Charlotte, North Carolina • Concord, North Carolina • Kings Mountain, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 27, 2026, 6:53 AM EDT
Recruiting No phase listed Observational

COPD Exacerbation Follow Up

NCT07118306
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
Not listed
Lead sponsor
Viz.ai, Inc.
Industry
Eligibility
40 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Park Ridge, Illinois • Cherry Hill, New Jersey • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 6:53 AM EDT
Active, not recruiting Phase 2 Interventional

Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT06175065
View directory record Official record
Conditions
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Interventions
RLS-0071, Placebo
Drug
Lead sponsor
ReAlta Life Sciences, Inc.
Industry
Eligibility
30 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
St. Petersburg, Florida • Glen Burnie, Maryland • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 27, 2026, 6:53 AM EDT
Not yet recruiting Phase 4 Interventional

Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)

NCT07721922
View directory record Official record
Conditions
COPD Exacerbation
Interventions
Revefenacin, formoterol fumarate, Placebo (Sterile Normal Saline), Albuterol sulfate, Ipratropium Bromide
Drug · Other
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Not applicable Interventional Results available

Digihaler in Chronic Obstructive Pulmonary Disease (COPD)

NCT05241288
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Albuterol eMDPI DS
Combination Product
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Not applicable Interventional

Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV

NCT01892566
View directory record Official record
Conditions
COPD, COPD Exacerbation
Interventions
mHealth Intervention
Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 100 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 27, 2026, 6:53 AM EDT
Completed No phase listed Observational

Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT00281242
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Interventions
blood draw
Other
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Not applicable Interventional

Tolerance and Acute Effects of a New HFNT Nasal Cannula

NCT05182294
View directory record Official record
Conditions
COPD Exacerbation Acute
Interventions
AIRVO 2, the new asymmetric nasal cannula
Device
Lead sponsor
Temple University
Other
Eligibility
40 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Inhaler Trainer Efficacy Study

NCT06461403
View directory record Official record
Conditions
Asthma, Copd, Acute Exacerbation of COPD
Interventions
Inhaler Trainer System, Initial Inhaler Use Assessment, Inhaler Use Instruction
Device · Other
Lead sponsor
Koronis Biomedical Technologies
Industry
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 27, 2026, 6:53 AM EDT
Not listed Not applicable Interventional

Breath-actuated Nebulizers in Acute COPD Exacerbations

NCT03985748
View directory record Official record
Conditions
COPD Exacerbation
Interventions
BAN, SN
Device
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 27, 2026, 6:53 AM EDT
Not listed No phase listed Observational

Steroid Resistance During COPD Exacerbations With Respiratory Failure

NCT03680495
View directory record Official record
Conditions
COPD, Emphysema or COPD, COPD Exacerbation, COPD Exacerbation Acute, Respiratory Failure, Ventilatory Failure
Interventions
Methylprednisolone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 89 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00739648
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
MP-376, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
40 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
39
States / cities
Haleyville, Alabama • Hueytown, Alabama • Mobile, Alabama + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Not applicable Interventional

The Reducing REVISITS Study: A Cluster RCT

NCT05568043
View directory record Official record
Conditions
COPD, COPD Exacerbation Acute
Interventions
COPD Transitions of Care Intervention Bundle: Virtual Interventions, COPD Transitions of Care Intervention Bundle: In-Person Interventions
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1

NCT01663987
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
49
States / cities
Birmingham, Alabama • Florence, Alabama • Fountain Valley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Phase 3 Interventional

Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis

NCT00473460
View directory record Official record
Conditions
Lung Diseases, Bronchitis, Chronic
Interventions
Avelox (Moxifloxacin, BAY12-8039), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 90 Years
Enrollment
1,404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
11
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 27, 2026, 6:53 AM EDT
Not listed Phase 2 Interventional

Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention

NCT05764993
View directory record Official record
Conditions
COPD Exacerbation Acute
Interventions
CUVITRU - Ig subcutaneous human 20%, Standard Medical Therapy
Biological · Other
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years to 82 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 27, 2026, 6:53 AM EDT
Completed No phase listed Observational

T Lymphocyte Cells in Individuals Experiencing an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT00281229
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Oct 27, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03345407
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 27, 2026, 6:53 AM EDT
Terminated Not applicable Interventional

Extracorporeal CO2 Removal With the Hemolung RAS for Mechanical Ventilation Avoidance During Acute Exacerbation of COPD

NCT03255057
View directory record Official record
Conditions
Acute Exacerbation of COPD
Interventions
Hemolung Respiratory Assist System, Invasive mechanical ventilation
Device
Lead sponsor
Alung Technologies
Industry
Eligibility
40 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
32
States / cities
Sacramento, California • Denver, Colorado • Newark, Delaware + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Not applicable Interventional Results available

Vibratory PEP Device and Hospital Length of Stay for Acute Exacerbation of COPD

NCT03094806
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Acapella Vibratory PEP Therapy Device plus usual care, Sham Acapella Vibratory PEP Device plus usual care
Device
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Not applicable Interventional

Effects of Nasal High-flow Oxygen in Patients With an Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03214458
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Nasal high flow
Device
Lead sponsor
Temple University
Other
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Oct 27, 2026, 6:53 AM EDT
Completed No phase listed Observational

Diastolic Dysfunction and Pauci-inflammatory Acute Exacerbations of COPD

NCT03110614
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Diastolic Dysfunction
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 27, 2026, 6:53 AM EDT
Completed Not applicable Interventional

Neuromuscular Electrical Stimulation in COPD/Community Acquired Pneumonia

NCT05452226
View directory record Official record
Conditions
Community-acquired Pneumonia, COPD Exacerbation Acute
Interventions
neuromuscular electrical stimulation (NMES)
Device
Lead sponsor
University of Vermont
Other
Eligibility
50 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 27, 2026, 6:53 AM EDT
Recruiting Phase 2 Interventional

Rademikibart IV for Acute Asthma and COPD Exacerbation

NCT07705737
View directory record Official record
Conditions
Asthma Acute, COPD Exacerbation Acute
Interventions
Rademikibart
Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Miami, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 27, 2026, 6:53 AM EDT